Top Markets
Coin of the day
Novo Nordisk A/S Novo Nordisk A/S

Novo Nordisk A/S

NVO
Rank in Stocks #98
Novo Nordisk A/S, a healthcare company, engages in the research, development,... Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Gilead Sciences, Inc. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Share Price
$38.05
Market Cap
$169.07B
Change (1 day)
0.22%
Change (1 year)
-50.38%
Country
DK
Trade Novo Nordisk A/S (NVO)

Category

P/B ratio for Novo Nordisk A/S (NVO)
P/B ratio as of February 2026 TTM: 7.11
According to Novo Nordisk A/S latest financial reports and stock price the company's current price-to-book ratio (TTM) is 7.11. At the end of 2026 the company had a P/B ratio of 0.
P/B ratio history for Novo Nordisk A/S from 2026 to 2026
P/B ratio at the end of each year
Year P/B Ratio Change
Not enough data for the provided dates.
P/B ratio for similar companies or competitors
Company P/B Ratio P/B Ratio Difference Country
6.3842 -10.24%
US
2.4551 -65.48%
US
4.364 -38.64%
BE
2.5504 -64.14%
AU
5.9034 -17.00%
NL